TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nuvocid® (Oritavancin) at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (SIMPLIFI)
Brief Summary: Two Phase III trials to demonstrate the efficacy and safety of oritavancin in the treatment of complicated skin and skin structure infections (cSSSI) have been completed.

The pharmacokinetic profile of oritavancin in humans suggests that oritavancin has the potential to be used safely and effectively when given either as a single dose or as an infrequent dose for cSSSI. Data from animals support this theory.

SIMPLIFI has been designed to evaluate the efficacy and safety of either a single dose of oritavancin or an infrequent dose of oritavancin (First dose on Day one with an option for a second dose on Day five) compared to the previously studied dosing regimen of 200mg oritavancin given once daily for 3 to 7 days.


Options:
A: Arm Label: Ceftaroline for Injection; Type: EXPERIMENTAL; Interventions: Drug: Ceftaroline | Arm Label: IV Vancomycin and IV Aztreonam; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV Vancomycin plus IV Aztreonam | Intervention Type: DRUG; Name: IV Vancomycin plus IV Aztreonam; Assigned to Arm(s): IV Vancomycin and IV Aztreonam | Intervention Type: DRUG; Name: Ceftaroline; Assigned to Arm(s): Ceftaroline for Injection
B: Arm Label: Ceftaroline fosamil for Injection; Type: EXPERIMENTAL; Interventions: Drug: ceftaroline, Drug: Placebo | Arm Label: IV Vancomycin plus IV Aztreonam; Type: ACTIVE_COMPARATOR; Interventions: Drug: vancomycin plus aztreonam | Intervention Type: DRUG; Name: ceftaroline; Assigned to Arm(s): Ceftaroline fosamil for Injection | Intervention Type: DRUG; Name: vancomycin plus aztreonam; Assigned to Arm(s): IV Vancomycin plus IV Aztreonam | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ceftaroline fosamil for Injection
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: oritavancin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: oritavancin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: oritavancin | Intervention Type: DRUG; Name: oritavancin; Assigned to Arm(s): 1, 2, 3
D: Arm Label: placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo group | Arm Label: antibiotic group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trimethoprim-sulfamethoxazole | Intervention Type: DRUG; Name: Trimethoprim-sulfamethoxazole; Assigned to Arm(s): antibiotic group | Intervention Type: DRUG; Name: Placebo group; Assigned to Arm(s): placebo group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of a School Disinfection and Hand Hygiene Program
Brief Summary: The objective of the trial is to assess the impact of a disinfection and hand hygiene program on absenteeism in elementary school classrooms. Students in intervention classrooms will use alcohol-based hand sanitizers at school, and their classrooms will be disinfected using quaternary ammonium wipes. We hypothesize that the use of disinfectants and hand hygiene products in elementary school classrooms will reduce absenteeism.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Alcohol-based hand sanitizer & quaternary ammonium wipes | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Alcohol-based hand sanitizer & quaternary ammonium wipes; Assigned to Arm(s): 1
B: Arm Label: Vitamin D and gargling; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D3), Behavioral: Gargling | Arm Label: Vitamin D and general health advice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D3) | Arm Label: Placebo and general health advice; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Placebo and gargling; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Gargling, Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol (vitamin D3); Assigned to Arm(s): Vitamin D and gargling, Vitamin D and general health advice | Intervention Type: BEHAVIORAL; Name: Gargling; Assigned to Arm(s): Placebo and gargling, Vitamin D and gargling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo and gargling, Placebo and general health advice
C: Arm Label: 1; Type: OTHER; Interventions: Other: Control | Arm Label: 2; Type: OTHER; Interventions: Device: Masks | Arm Label: 3; Type: OTHER; Interventions: Device: Masks & hand hygiene | Intervention Type: DEVICE; Name: Masks; Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: Masks & hand hygiene; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): 1
D: Arm Label: State of the Art strategy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: state-of-the art strategy and extented strategy | Arm Label: extended strategy; Type: EXPERIMENTAL; Interventions: Behavioral: state-of-the art strategy and extented strategy | Intervention Type: BEHAVIORAL; Name: state-of-the art strategy and extented strategy; Assigned to Arm(s): State of the Art strategy, extended strategy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of a School Disinfection and Hand Hygiene Program
Brief Summary: The objective of the trial is to assess the impact of a disinfection and hand hygiene program on absenteeism in elementary school classrooms. Students in intervention classrooms will use alcohol-based hand sanitizers at school, and their classrooms will be disinfected using quaternary ammonium wipes. We hypothesize that the use of disinfectants and hand hygiene products in elementary school classrooms will reduce absenteeism.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: health education | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: hand hygiene | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: hand hygiene, Device: face masks | Intervention Type: BEHAVIORAL; Name: hand hygiene; Assigned to Arm(s): 2, 3 | Intervention Type: OTHER; Name: health education; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: face masks; Assigned to Arm(s): 3
B: Intervention Type: PROCEDURE; Name: Laparotomy+ HIPEC +/- CRS; Assigned to Arm(s): N/A
C: Arm Label: Hand washing; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Hand washing | Arm Label: Disinfectant rubbing; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Disinfectant rubbing | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Hand washing; Assigned to Arm(s): Hand washing | Intervention Type: BEHAVIORAL; Name: Disinfectant rubbing; Assigned to Arm(s): Disinfectant rubbing
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Alcohol-based hand sanitizer & quaternary ammonium wipes | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Alcohol-based hand sanitizer & quaternary ammonium wipes; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of a School Disinfection and Hand Hygiene Program
Brief Summary: The objective of the trial is to assess the impact of a disinfection and hand hygiene program on absenteeism in elementary school classrooms. Students in intervention classrooms will use alcohol-based hand sanitizers at school, and their classrooms will be disinfected using quaternary ammonium wipes. We hypothesize that the use of disinfectants and hand hygiene products in elementary school classrooms will reduce absenteeism.


Options:
A: Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 3804-250A lotion; Type: EXPERIMENTAL; Interventions: Drug: 3804-250A | Intervention Type: DRUG; Name: 3804-250A; Assigned to Arm(s): 3804-250A lotion
B: Arm Label: Normal recommendations, no mask; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Normal recommendations AND mask; Type: EXPERIMENTAL; Interventions: Other: Surgical facial mask | Intervention Type: OTHER; Name: Surgical facial mask; Assigned to Arm(s): Normal recommendations AND mask
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Alcohol-based hand sanitizer & quaternary ammonium wipes | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Alcohol-based hand sanitizer & quaternary ammonium wipes; Assigned to Arm(s): 1
D: Arm Label: State of the Art strategy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: state-of-the art strategy and extented strategy | Arm Label: extended strategy; Type: EXPERIMENTAL; Interventions: Behavioral: state-of-the art strategy and extented strategy | Intervention Type: BEHAVIORAL; Name: state-of-the art strategy and extented strategy; Assigned to Arm(s): State of the Art strategy, extended strategy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community Based Trial of Home Blood Pressure Monitoring With Nurse Led Support in Patients With Stroke or TIA Recently Discharged From Hospital
Brief Summary: Design: Community based randomised trial with follow up after 12 months Participants: 360 patients admitted with stroke or TIA within the past 9 months will be recruited from the wards or outpatients and randomly allocated into two groups. All patients will be visited by the specialist nurse at home at baseline when she will measure their BP and administer a questionnaire. The questionnaire and BP will be repeated at 12 months follow-up by another researcher blind as to whether the patient is in intervention or control group.

Intervention: Intervention patients will be given a validated home BP monitor and support from the specialist nurse. Control patients will continue with usual care (BP monitoring by their practice).

Main outcome measures in both groups after 12months: 1.Change in systolic BP 2.Cost effectiveness: Incremental cost of the intervention to the NHS and incremental cost per quality adjusted life year gained.

Study hypothesis. Home blood pressure monitoring with nurse support wil lead to lower blood pressure after 12 months compared with usual GP care


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention - a validated home BP monitor and support from the specialist nurse | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control - usual care (BP monitoring by their practice) | Intervention Type: BEHAVIORAL; Name: Intervention - a validated home BP monitor and support from the specialist nurse; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Control - usual care (BP monitoring by their practice); Assigned to Arm(s): Control
B: Arm Label: Behavioral; Type: EXPERIMENTAL; Interventions: Behavioral: Smart-phone based technology | Arm Label: Usual background care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Smart-phone based technology; Assigned to Arm(s): Behavioral
C: Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Intensive pharmacist case management; Type: EXPERIMENTAL; Interventions: Drug: Antihypertensive agents and lipid lowering therapy | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: DRUG; Name: Antihypertensive agents and lipid lowering therapy; Assigned to Arm(s): Intensive pharmacist case management | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community Based Trial of Home Blood Pressure Monitoring With Nurse Led Support in Patients With Stroke or TIA Recently Discharged From Hospital
Brief Summary: Design: Community based randomised trial with follow up after 12 months Participants: 360 patients admitted with stroke or TIA within the past 9 months will be recruited from the wards or outpatients and randomly allocated into two groups. All patients will be visited by the specialist nurse at home at baseline when she will measure their BP and administer a questionnaire. The questionnaire and BP will be repeated at 12 months follow-up by another researcher blind as to whether the patient is in intervention or control group.

Intervention: Intervention patients will be given a validated home BP monitor and support from the specialist nurse. Control patients will continue with usual care (BP monitoring by their practice).

Main outcome measures in both groups after 12months: 1.Change in systolic BP 2.Cost effectiveness: Incremental cost of the intervention to the NHS and incremental cost per quality adjusted life year gained.

Study hypothesis. Home blood pressure monitoring with nurse support wil lead to lower blood pressure after 12 months compared with usual GP care


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: telemedicine | Intervention Type: OTHER; Name: telemedicine; Assigned to Arm(s): 2
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention - a validated home BP monitor and support from the specialist nurse | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control - usual care (BP monitoring by their practice) | Intervention Type: BEHAVIORAL; Name: Intervention - a validated home BP monitor and support from the specialist nurse; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Control - usual care (BP monitoring by their practice); Assigned to Arm(s): Control
C: Arm Label: CONTROL group; Type: ACTIVE_COMPARATOR; Interventions: Other: Home Monitoring | Arm Label: ACTIVE group; Type: EXPERIMENTAL; Interventions: Other: Home Monitoring | Intervention Type: OTHER; Name: Home Monitoring; Assigned to Arm(s): ACTIVE group, CONTROL group
D: Arm Label: Remote Arm; Type: N/A; Interventions: Device: The Medtronic CareLink system (Minneapolis, MN, USA). | Arm Label: Implantable defibrillator patients; Type: N/A; Interventions: Device: The Medtronic CareLink system (Minneapolis, MN, USA). | Intervention Type: DEVICE; Name: The Medtronic CareLink system (Minneapolis, MN, USA).; Assigned to Arm(s): Implantable defibrillator patients, Remote Arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Brief Intervention for Regular Prescription Drug Use and Prescription Drug Use Disorders in General Hospital
Brief Summary: In a randomized controlled trial, patients recruited in a general hospital and fulfilling criteria for regular consumption (more than 60 days within the last three months), dependence or abuse of prescription drugs will be randomly allocated to two conditions:(1) Intervention group consisting of two counselling sessions based on Motivational Interviewing plus a personalized feedback, (2) Control group receiving a booklet on health behavior.

Outcome assessment will be conducted after 12 months. The hypothesis is that counseling leads to greater reduction in consumption of prescription drugs (including discontinuation) and elevated readiness to change at follow-up.


Options:
A: Arm Label: Motivational Interviewing (MI); Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing (MI) | Arm Label: Brief Adolescent Mindfulness (BAM); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Adolescent Mindfulness (BAM) | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing (MI); Assigned to Arm(s): Motivational Interviewing (MI) | Intervention Type: BEHAVIORAL; Name: Brief Adolescent Mindfulness (BAM); Assigned to Arm(s): Brief Adolescent Mindfulness (BAM)
B: Arm Label: C; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: MI; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): MI
C: Arm Label: Brief motivational interview; Type: EXPERIMENTAL; Interventions: Behavioral: Brief motivational interview | Arm Label: No discussion; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Brief motivational interview; Assigned to Arm(s): Brief motivational interview
D: Arm Label: Motivational Enhancement Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Enhancement Therapy (MET) | Arm Label: Health Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health education | Intervention Type: BEHAVIORAL; Name: Motivational Enhancement Therapy (MET); Assigned to Arm(s): Motivational Enhancement Therapy | Intervention Type: BEHAVIORAL; Name: Health education; Assigned to Arm(s): Health Education

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Brief Intervention for Regular Prescription Drug Use and Prescription Drug Use Disorders in General Hospital
Brief Summary: In a randomized controlled trial, patients recruited in a general hospital and fulfilling criteria for regular consumption (more than 60 days within the last three months), dependence or abuse of prescription drugs will be randomly allocated to two conditions:(1) Intervention group consisting of two counselling sessions based on Motivational Interviewing plus a personalized feedback, (2) Control group receiving a booklet on health behavior.

Outcome assessment will be conducted after 12 months. The hypothesis is that counseling leads to greater reduction in consumption of prescription drugs (including discontinuation) and elevated readiness to change at follow-up.


Options:
A: Arm Label: 1) assessment plus motivational interview; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: motivational interviewing | Intervention Type: BEHAVIORAL; Name: motivational interviewing; Assigned to Arm(s): 1) assessment plus motivational interview
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adapted Motivational Interviewing & Skills Training | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adapted Motivational Interviewing & Skills Training | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Adapted Motivational Interviewing & Skills Training; Assigned to Arm(s): 1, 2
C: Intervention Type: BEHAVIORAL; Name: Brief Intervention (adaptation of motivational interviewing); Assigned to Arm(s): N/A
D: Arm Label: C; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: MI; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): MI

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Impact on Mortality and Morbidity of the WHO Recommended Vitamin A Supplementation at First Immunisation Contact After 6 Months of Age
Brief Summary: High-dose vitamin A to children above 6 months of age reduces all-cause mortality by 23-30%. The WHO recommends vitamin A supplementation (VAS) with the first vaccine after 6 months of age. However, the effect of providing VAS with vaccines has never been investigated. We have hypothesised that the effect of VAS depends on the immune stimulus at the time of supplementation. Hence, the effect might vary depending on which type of vaccine it is given with. In particular, we hypothesised that VAS might be beneficial when given with measles vaccine but not when given with DTP vaccine. Normally the first vaccine after 6 months of age would be a measles vaccine, but many children come late for their DTP vaccinations and receive DTP alone or together with measles vaccine. Hence, it is important to study whether the effect of VAS is the same irrespective of the vaccine(s) administered at the same time.

Guinea-Bissau has not yet implemented the WHO vitamin A policy of providing VAS with vaccines, but plans to do so within the next years. Together with the Ministry of Health in Guinea-Bissau, the Bandim Health Project (BHP) in Guinea-Bissau will investigate the effect on mortality and morbidity of implementing the WHO vitamin A policy in Guinea-Bissau. This will be done in a large randomised trial.

BHP has a demographic surveillance system (DSS) which has followed a population of now more than 150,000 individuals for almost 30 years. Children will be randomised to receive VAS or placebo with their first vaccine after 6 months of age, and will be followed through the DSS to assess mortality and morbidity. Based on previous observations, the effects of VAS might differ according to sex and season. The interaction between VAS, sex, and season will also be studied in the present trial. By identifying situations where VAS may be beneficial, ineffective, or even harmful the study may contribute importantly to optimising the VAS policy for low-income countries.


Options:
A: Intervention Type: DRUG; Name: Vitamin + Zinc + micronutrient mixture; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A + Zinc; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A
C: Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Vitamin A | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Vitamin A | Intervention Type: BIOLOGICAL; Name: Vitamin A; Assigned to Arm(s): 1, 2

Answer: D